Basiliximab for Injection

Basiliximab for injection is a Western medicine. Clinically, basiliximab is used to prevent early acute organ rejection after renal transplantation.
This product is usually used in combination with a dual immunosuppressant therapy based on cyclosporine and corticosteroids (adults and children) or a long-term triple immunosuppressant therapy based on cyclosporine, corticosteroids and azathioprine/mycophenolate mofetil (adults only).
Basiliximab is a mouse/human chimeric monoclonal antibody (IgG1κ) that can antagonize the receptor α chain (CD25 antigen) of interleukin-2 (IL-2). The CD25 antigen is expressed on the surface of T-lymphocytes in the body’s response to foreign antigen stimulation. Activated T-lymphocytes have a very high affinity for IL-2, and basiliximab can specifically bind to the CD25 antigen on activated T-lymphocytes with high affinity (KD value is 0.1nM), thereby blocking the binding of IL-2 to the IL-2 receptor, that is, blocking the transmission of T-cell proliferation information.